{"id":"NCT00464815","sponsor":"GlaxoSmithKline","briefTitle":"Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects","officialTitle":"Primary Vaccination Study in Subjects Aged 11-17 Years to Demonstrate the Non-inferiority of GSK Biologicals' Meningococcal Vaccine GSK134612 Vaccine Versus Mencevax™ ACWY","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-05-02","primaryCompletion":"2008-04-16","completion":"2008-09-10","firstPosted":"2007-04-24","resultsPosted":"2018-04-02","lastUpdate":"2018-06-08"},"enrollment":1025,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Meningococcal"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal vaccine GSK134612","otherNames":[]},{"type":"BIOLOGICAL","name":"Mencevax™ ACWY","otherNames":[]}],"arms":[{"label":"Group A","type":"EXPERIMENTAL"},{"label":"Group B","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to demonstrate, in 11-17 year old subjects, the non-inferiority of meningococcal vaccine GSK134612 compared to licensed meningococcal vaccine Mencevax™.","primaryOutcome":{"measure":"Number of Subjects With Vaccine Response to Meningococcal Antigens","timeFrame":"One month post-vaccination (At Month 1)","effectByArm":[{"arm":"Nimenrix Group","deltaMin":472,"sd":null},{"arm":"Mencevax ACWY Group","deltaMin":148,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"11 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":16},"locations":{"siteCount":7,"countries":["India","Philippines","Taiwan"]},"refs":{"pmids":["21343698"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":768},"commonTop":["Pain","Fatigue","Headache","Redness","Swelling"]}}